{
    "clinical_study": {
        "@rank": "99401", 
        "arm_group": [
            {
                "arm_group_label": "1", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "2", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purposes of this study are to learn whether treatment with an androgen type hormone will\n      improve the visual-spatial problems associated with Turner syndrome, and to evaluate the\n      effect growth hormone, with and without androgen, has on growth."
        }, 
        "brief_title": "The Effect of Androgen and Growth Hormone on Height and Learning in Girls With Turner Syndrome", 
        "completion_date": {
            "#text": "June 2012", 
            "@type": "Actual"
        }, 
        "condition": "Turner Syndrome", 
        "condition_browse": {
            "mesh_term": [
                "Turner Syndrome", 
                "Gonadal Dysgenesis", 
                "Primary Ovarian Insufficiency"
            ]
        }, 
        "detailed_description": {
            "textblock": "Turner syndrome is associated with short stature, multiple physical stigmata, absent\n      pubertal development, and increased learning problems.  This study is designed to (1)\n      examine the effects of sex steroids (androgen and estrogen) on multiple variables including\n      growth rate, GH binding protein, IGF-I, IGFBP3, and cognitive function in the setting of\n      supplemental growth hormone administration and (2) to investigate any synergistic or\n      additive effects of the androgen and estrogen combination versus each alone, on the above\n      variables."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "-  Karyotype diagnosis compatible with Turner syndrome, but no presence of any Y\n             material in the peripheral karyotype unless a gonadectomy has been performed;\n\n          -  Chronological age between 10.0 and 14.9 years;\n\n          -  Bone age less than or equal to 12 years; and\n\n          -  No treatment with estrogen, androgen, growth hormone, or any other growth-promoting\n             agents exceeding 12 months, and no treatment with any of these agents in the previous\n             3 months."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "14 Years", 
            "minimum_age": "10 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 8, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00029159", 
            "org_study_id": "R01NS32531"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "1", 
                    "2"
                ], 
                "description": "Participants were started on ethinyl estradiol at a daily dose of 50ng/kg at the beginning of the 3rd year of the study. The estrogen was continued until study end.", 
                "intervention_name": "estrogen", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "1", 
                "description": "Oxandrolone or placebo capsule, .06mg/kg/day, orally, for 2 years", 
                "intervention_name": "androgen", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "2", 
                "description": "an inactive substance", 
                "intervention_name": "placebo", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Androgens", 
                "Estrogens", 
                "Hormones"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Turner syndrome", 
            "estrogen", 
            "androgen", 
            "growth hormone"
        ], 
        "lastchanged_date": "June 4, 2012", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Bethesda", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "20892"
                    }, 
                    "name": "National Institutes of Health"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19102"
                    }, 
                    "name": "Thomas Jefferson University Hospital, 1025 Walnut Street, Suite 726"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Effects of Androgen, Estrogen, and the Combination of Androgen and Estrogen on Growth Rate and Cognitive Function of Growth Hormone-treated Girls With Turner Syndrome", 
        "overall_official": {
            "affiliation": "Thomas Jefferson University", 
            "last_name": "Judith L. Ross, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United States: Federal Government", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2007", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Cognitive function in girls with Turner Syndrome", 
            "safety_issue": "Yes", 
            "time_frame": "4 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00029159"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Thomas Jefferson University", 
        "sponsors": {
            "collaborator": {
                "agency": "National Institute of Neurological Disorders and Stroke (NINDS)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Thomas Jefferson University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 1992", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2012"
    }, 
    "geocoordinates": {
        "National Institutes of Health": "38.985 -77.095", 
        "Thomas Jefferson University Hospital, 1025 Walnut Street, Suite 726": "39.952 -75.164"
    }
}